Caribou Biosciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Caribou Biosciences, Inc. (CRBU) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Caribou Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.48M, a 20.84% decline year-over-year.
- Caribou Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.36M, a 39.28% decline year-over-year.
- Caribou Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.93M, a 27.97% decline year-over-year.
- Caribou Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.13M, a 33.96% decline year-over-year.
- Caribou Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $16.71M, a 21.50% increase from fiscal 2023.
- Caribou Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $13.75M, a 17.37% increase from fiscal 2022.
- Caribou Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $11.71M, a 239.66% increase from fiscal 2021.
- Caribou Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $3.45M, a 244.21% increase from fiscal 2020.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.48M 10-Q · filed 2026-08-13 | $4.83M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $2.36M 10-Q · filed 2026-08-13 | |||
| 2025-09-30 | $2.93M 10-Q · filed 2025-11-12 | $6.06M derived: sum of 2 quarters · filed 2026-08-13 | $9.94M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $3.13M 10-Q · filed 2026-08-13 | $7.01M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $3.88M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $16.71M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $4.07M 10-Q · filed 2025-11-12 | $8.81M derived: sum of 2 quarters · filed 2025-11-12 | $12.79M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $4.74M 10-Q · filed 2025-11-12 | $8.73M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $3.99M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $13.75M 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $3.48M 10-Q · filed 2024-11-06 | $7.06M derived: sum of 2 quarters · filed 2024-11-06 | $10.19M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $3.58M 10-Q · filed 2024-11-06 | $6.72M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $3.13M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $11.71M 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $2.67M 10-Q · filed 2023-11-07 | $5.59M derived: sum of 2 quarters · filed 2023-11-07 | $8.61M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $2.92M 10-Q · filed 2023-11-07 | $5.94M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $3.02M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $3.45M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $935.00K 10-Q · filed 2022-11-08 | $1.53M derived: sum of 2 quarters · filed 2022-11-08 | $1.87M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $593.00K 10-Q · filed 2022-11-08 | $936.00K derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $343.00K 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $1.00M 10-K · filed 2022-03-21 | |||
| 2020-09-30 | $248.00K 10-Q · filed 2021-11-09 | $534.00K derived: sum of 2 quarters · filed 2021-11-09 | $771.00K derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $286.00K 10-Q · filed 2021-11-09 | $523.00K derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $237.00K 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $1.23M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |